Pharmaceutical Investing Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
Pharmaceutical Investing Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
Pharmaceutical Investing Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
Pharmaceutical Investing Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
Pharmaceutical Investing Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding
